EGFR and neoplasm: In an osimertinib-resistant EGFR ex19del/T790M/C797S mouse model derived from a patient with an NSCLC tumor who progressed after treatment with gefitinib and osimertinib, the tumor growth was inhibited by BLU-945 [198].